AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$PRLD

Prelude Therapeutics Inc

Price · $PRLDvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $PRLD in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $PRLD in the last 30 days.

Top stories · $PRLDMore →
JUL 29·rttnews.comMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

JUN 10·SEC EDGAR 8-K

Prelude Therapeutics Inc (PRLD): Submission of Matters to a Vote of Security Holders

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2

APR 27·GuruFocus

PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8

HC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating for Prelude Therapeutics (PRLD) and raised the price target to $8 from $5, a 60% increase. The positive outlook is based on the company's innovative pipeline in oncology. Despite a low GF Score™ of 37/100, indicating financial challenges, insider buying of $25.0 million in the past three months suggests confidence in the company's future.

PRLD sentiment & insider activity

Recent PRLD coverage spans financial news, market movers and corporate actions.

What's driving PRLD

  • This looks more like sentiment/flow than a new fundamental catalyst, so follow-through risk is higher.

    rttnews.com · Jul 29, 2026

  • Routine corporate governance outcomes; unlikely to change near-term fundamentals, but confirms board/accounting/compensation framework for the year.

    SEC EDGAR 8-K · Jun 10, 2026

  • The analyst upgrade and increased price target suggest positive sentiment towards Prelude Therapeutics, potentially indicating a bullish outlook. Insider buying further supports confidence in the company's future prospects.

    GuruFocus · Apr 27, 2026

  • Preclinical data for PRT13722 indicates promising efficacy and safety profiles, potentially supporting positive stock movement.

    GlobeNewswire · Apr 20, 2026

  • The investigation may lead to negative sentiment and potential stock decline if allegations are substantiated; however, the news is currently at an early stage with limited concrete evidence.

    Benzinga · Nov 26, 2025

alphai scores every news story that mentions PRLD with an AI model for sentiment and relevance, and aggregates insider trades from Prelude Therapeutics Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PRLD

Score
JUL 29$TRIBMedrttnews.com

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

7 min read
JUN 10$PRLDLowSEC EDGAR 8-K

Prelude Therapeutics Inc (PRLD): Submission of Matters to a Vote of Security Holders

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2

3 min read
APR 27$PRLDMedGuruFocus

PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8

HC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating for Prelude Therapeutics (PRLD) and raised the price target to $8 from $5, a 60% increase. The positive outlook is based on the company's innovative pipeline in oncology. Despite a low GF Score™ of 37/100, indicating financial challenges, insider buying of $25.0 million in the past three months suggests confidence in the company's future.

3 min read
APR 20$PRLDMedGlobeNewswire

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class, orally bioavailable KAT6A degrader for HR+/HER2- breast cancer. The data show potential for differentiated efficacy and safety, including complete responses as monotherapy in various models. Prelude aims to file an Investigational New Drug (IND) application by mid-2026 and initiate a clinical trial in the second half of 2026.

3 min read

Related tickers

More in Biotechnology